摘要
目的了解成年人伴CD2表达B系急性淋巴细胞白血病（CD2^＋ B—ALL）的免疫表型特征，为临床诊断、治疗及预后判断提供依据。方法应用流式细胞术及多种单克隆抗体检测18例成年人CD2^＋B—ALL及68例CDiB—ALL患者的免疫表型，并对其结果进行分析比较。结果CD2^＋ B—ALL的发病年龄明显小于CD2B—ALL，18例成年人CD2^＋B、ALL的大部分表面标志物与CD2^- B．ALL相似，其中CD10表达水平[（73．78±26．67）％廊于CD2^- B—ALL[（52．84±35．25）％]，差异有统计学意义（t=2．35，P〈0．05），CD33表达水平[（15．46±27，41）％]则低于CD2B—ALL[（31．15±27．72）％]，差异有统计学意义（t=2．16，P〈0．05）；所有B—ALL患者都高表达CD。，阳性表达率分别为72．2％（13／18）和80．9％（55／68），差异无统计学意义（x^2=0．64，P〉0．05）。CD2^＋ B—ALL的CD20阳性率明显低于CD2^- B—ALL，差异有统计学意义（x^2=11．38，P〈0．05）。CD2^＋B—ALL伴髓系抗原（CD13，或CD33）表达率为44．4％（8／18），明显低于CD2^-B—ALL的72．1％（49／68），差异有统计学意义（x^2=4．86，P〈0．05）。结论成年人CD2^＋ B—ALL与CD2^- B—ALL具有相似的免疫表型，主要来源于造血干细胞的恶性转化，CD2^＋ B—ALL伴髓系抗原（CD13,CD33）及CD20表达明显低于CD2^- B—ALL，提示成年人CD2^＋ B—ALL可能有较好的预后。
Objective To study the immunophenotypic feature of CD2^＋ adult B cell acute lymphoblastic leukemia （CD2^＋ B-ALL） and provide evidences for the diagnosis, therapy and prognosis. Methods The immunophenotypes of 18 cases of adult CD2^＋ B-ALL and 68 cases of adult CD2^- B cell acute lymphoblastic leukemia（CD2^- B-ALL） were assayed by a panel of monoclonal antibodies （McAbs） with FACS. Results The age of CD2^＋ B-ALL adults was younger compared to that of CD2^- B-ALL. The patients in the CD2^＋ group were similar to CD2^＋ group for the expression of most of the cell surface antigens assayed. However, it was notable that expression frequencies of CD10 [（73.78±26.67） %] in CD2^＋ B-ALL was higher than those in CD2 B-ALL [（52.84±35.25） %] （t = 2.35, P 〈0.05） and CD33 [（15.46±27.41） %] were significantly lower than that of CD2^＋ B- ALL [（31.15±27.72） %] （t = 2.16, P 〈0.05）. Both groups showed high positive expression for CD34 72.2 % （13/ 18） and 80.9 % （55/68）, respectively （X^2 = 0.64, P 〉0.05）. The CD20 expression in CD2^＋ B-ALL was lower than that in CD2 B-ALL significantly （X^2 = 11.38, P 〈0.05）. The myeloid antigen （CD13 or CD33） expression in CD2^＋ B-ALL 44.4 % （8/18） was lower than that in CD2^- B-ALL 72.1%（49/68） （X^2 = 4.86, P 〈0.05）. Conclusion Patients in the CD2^＋ B-ALL were similar to CD2 B-ALL for expression of most of the cell surface antigens assayed. CD2^＋ B-ALL showed low expression frequency of myeloid antigens （CD13, CD33） and CD20 antigens than CD2^＋ B-ALL. These results suggested that those with the CD2^＋ B-ALL immunophenotype generally presented with favorable prognostic features and usually could achieve good outcomes after treatment.
出处
《白血病．淋巴瘤》
CAS
2011年第7期392-394,共3页
Journal of Leukemia & Lymphoma
